Three experts on oncology will talk about the convenience and efficiency of opting for one of the three cyclin inhibitors that are currently used to treat breast cancer: ribociclib, abemaciclib and palbociclib. During the debate, there will be a questionnaire to know the attendees' perception of the different treatments. At the end of the debate there will be a round of questions.
The debate will be given by Maria Bidal, from Hospital Clínic-IDIBAPS; Meritxell Bellet, from the Vall d'Hebron Barcelona University Campus, and Mireia Margelí, from ICO Badalona-B·ARGO. It will be chaired by ALeix Prat, director of the Innovation Chair on Precision Oncology of the UB and head of the Department of Medical Oncology of the Hospital Clínic-IDIBAPS.
Further information